The most‑cited independent voice on peptide therapy.
Science journalism, not medical advice — written for performance‑minded adults watching the peptide landscape ahead of FDA reclassification. We read the file. We date every claim. We sell nothing — yet.
A favourable vote is not a prescription you can fill in August.
PCAC — the Pharmacy Compounding Advisory Committee. Advisory, not binding; the rulemaking that follows is where access actually changes.
Editorial coverage
We read and date every file. Nothing is for sale.
PCAC review
FDA's advisory committee hears seven peptides at White Oak.
The vote
A non‑binding recommendation, taken peptide by peptide.
FDA rulemaking
The recommendation becomes a rule. Here is where access changes.
Legal access
Licensed pharmacies may dispense by prescription. We open.
Every peptide we track. One file each.
The peptides we cover — each with its evidence tag and where it sits in the FDA’s compounding review. We don’t promote a compound past its data, and we say so on every line.
What the literature actually says.
TB-500 and Thymosin β4: Where the Repair Evidence Actually Is — and Where It Isn't
TB-500's entire tendon record is one in-vitro dish. Here's where the animal evidence genuinely is strong, why the vial is a separate problem, and what the July 2026 FDA review actually means.
The Wolverine Stack: what BPC-157 and TB-500 together could do
The peptide the FDA already voted against
What BPC-157 actually does: the plain answer on the repair peptide
What GHK-Cu actually does — the plain answer
Peptide access by US state: why the regulatory patchwork right now is real
Science journalism. Not medical advice. We keep the difference visible.
How we rate the evidence.
Every claim carries one of three tags — human trials, animal data, or not yet known. If the literature is thin, the language is thin. We cite the trial phase, not a slogan.
What we don’t do.
No protocols. No dosing. No products, until the law changes. We don’t prescribe, and we don’t pretend a forum post is a study. We are not your doctor — we say so, repeatedly.
Who writes this.
Independent editors who read primary literature and FDA dockets directly. Every file is dated and re‑reviewed. When a file changes, the date changes with it.
Be on the list the day the window opens.
When reclassification lands, this becomes a physician‑supervised pharmacy. The waitlist goes first — and gets the briefing every week in the meantime. No spam. No products until it's legal. If we ever can't help you, we'll say so on screen.
You're on the list. Check your inbox for the first briefing.
We send the regulatory briefing weekly and tell you the day prescriptions become fillable in your state. Unsubscribe in one click.